Spectranetics Cp T (SPNC) 24.86 $SPNC
Spectranetics Has Returned 25.8% Since SmarTrend Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 30, 1:41PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.82% as of today's recent price of $25.09.
SPNC: 24.86 (+0.17)
Spectranetics Shares Up 25.6% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 23, 1:15AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.60% as of today's recent price of $25.05.
SPNC: 24.86 (+0.17)
Technical Roundup on Medical Appliances & Equipment Stocks -- Zimmer Biomet, Stryker, ABIOMED, and Spectranetics
PR Newswire - Thu Aug 18, 7:31AM CDT
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
SPNC: 24.86 (+0.17), ABMD: 117.43 (-0.20), ZBH: 129.40 (+1.05), SYK: 115.60 (+0.37)
First Randomized Trial of the Stellarex(TM) Drug-coated Balloon Presented at the Amputation Prevention Symposium
GlobeNewswire - Wed Aug 10, 4:58PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria, presented the final 12-month results of the Stellarex Drug-coated Balloon ILLUMENATE European Randomized Clinical Trial (EU RCT) at the Amputation Prevention Symposium (AMP) in Chicago, Illinois. The EU RCT Trial enrolled 328 patients, 295 of whom were randomized to treatment with the Stellarex drug-coated balloon (DCB) or a percutaneous transluminal angioplasty (PTA). The key results at day 365 include:
SPNC: 24.86 (+0.17)
Spectranetics Receives CE Mark for AngioSculptX(TM)
GlobeNewswire - Wed Aug 10, 8:00AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a drug coating. It is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis.
SPNC: 24.86 (+0.17)
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Wed Aug 10, 3:27AM CDT
Spectranetics (NASDAQ:SPNC) was downgraded from Strong Buy to Buy at Needham today. The stock closed yesterday at $24.03 on volume of 445,000 shares, below average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)
Upgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Thu Aug 04, 3:16AM CDT
Spectranetics (NASDAQ:SPNC) was upgraded from Sell to Buy at UBS today. The stock closed yesterday at $23.67 on volume of 1.1 million shares, above average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)
Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million
GlobeNewswire - Thu Jul 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended June 30, 2016. Highlights of the quarter, all compared with the three months ended June 30, 2015, include:
SPNC: 24.86 (+0.17)
Uptrend Call Working As Spectranetics Stock Rises 28.4% (SPNC)
Comtex SmarTrend(R) - Fri Jun 10, 1:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 28.41% as of today's recent price of $19.82.
SPNC: 24.86 (+0.17)
How are These Healthcare Stocks Faring? - Zimmer Biomet, Wright Medical, Spectranetics and Prestige Brands
PR Newswire - Fri Jun 03, 7:00AM CDT
In today's pre-market coverage, ActiveWallSt.com has these four Medical Appliances and Equipment stocks lined up for investors to review: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Wright Medical Group N.V. (NASDAQ: WMGI), The Spectranetics Corp. (NASDAQ: SPNC), and Prestige Brands Holdings Inc. (NYSE: PBH). Register now to access these stocks' trade alerts by clicking on the following link:
SPNC: 24.86 (+0.17), ZBH: 129.40 (+1.05), WMGI: 24.71 (+0.10), PBH: 47.99 (+0.29), WMGIZ: 1.35 (unch)
Shares of SPNC Up 26.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:55PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 26.27% as of today's recent price of $19.49.
SPNC: 24.86 (+0.17)
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
GlobeNewswire - Wed Jun 01, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)
SmarTrend Watching for Potential Pullback in Shares of Spectranetics After 5.77% Gain
Comtex SmarTrend(R) - Mon May 23, 4:32PM CDT
Spectranetics (NASDAQ:SPNC) traded in a range yesterday that spanned from a low of $16.56 to a high of $17.72. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $17.39 on volume of 534,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SPNC: 24.86 (+0.17)
Spectranetics to Present at the UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS Global Healthcare Conference on May 25, 2016, at the Grand Hyatt in New York City.
SPNC: 24.86 (+0.17)
Spectranetics reports 1Q loss
Automated Insights - Thu Apr 28, 6:28PM CDT
COLORADO SPRINGS, Colo. (AP) _ The Spectranetics Corp. (SPNC) on Thursday reported a loss of $17.3 million in its first quarter.
SPNC: 24.86 (+0.17)
Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
GlobeNewswire - Thu Apr 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. Highlights of the quarter, all compared with the three months ended March 31, 2015, include:
SPNC: 24.86 (+0.17)
12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
GlobeNewswire - Tue Apr 26, 5:30AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in London, England. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)
Spectranetics Has Returned 25.8% Since SmarTrend Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 30, 1:41PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.82% as of today's recent price of $25.09.
SPNC: 24.86 (+0.17)
Spectranetics Shares Up 25.6% Since SmarTrend's Buy Recommendation (SPNC)
Comtex SmarTrend(R) - Tue Aug 23, 1:15AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on July 7th, 2016 at $19.95. In approximately 2 months, Spectranetics has returned 25.60% as of today's recent price of $25.05.
SPNC: 24.86 (+0.17)
Technical Roundup on Medical Appliances & Equipment Stocks -- Zimmer Biomet, Stryker, ABIOMED, and Spectranetics
PR Newswire - Thu Aug 18, 7:31AM CDT
Stock-Callers.com is currently focused on the Medical Appliances and Equipment segment, which includes companies that manufacture medical supplies such as surgical and medical instruments, dental equipment, and surgical appliances. According to IBISWorld, global revenue of this industry is about $350 billion. Let us take a look at today's lineup: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Stryker Corp. (NYSE: SYK), ABIOMED Inc. (NASDAQ: ABMD), and The Spectranetics Corp. (NASDAQ: SPNC). Sign up today and download for free the research reports for the stocks covered today at:
SPNC: 24.86 (+0.17), ABMD: 117.43 (-0.20), ZBH: 129.40 (+1.05), SYK: 115.60 (+0.37)
First Randomized Trial of the Stellarex(TM) Drug-coated Balloon Presented at the Amputation Prevention Symposium
GlobeNewswire - Wed Aug 10, 4:58PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Marianne Brodmann of Medical University Graz, Austria, presented the final 12-month results of the Stellarex Drug-coated Balloon ILLUMENATE European Randomized Clinical Trial (EU RCT) at the Amputation Prevention Symposium (AMP) in Chicago, Illinois. The EU RCT Trial enrolled 328 patients, 295 of whom were randomized to treatment with the Stellarex drug-coated balloon (DCB) or a percutaneous transluminal angioplasty (PTA). The key results at day 365 include:
SPNC: 24.86 (+0.17)
Spectranetics Receives CE Mark for AngioSculptX(TM)
GlobeNewswire - Wed Aug 10, 8:00AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced receipt of CE marking for the AngioSculptX Drug-coated PTCA Scoring Balloon Catheter. AngioSculptX is a first-of-its-kind device, combining the proven AngioSculpt PTCA scoring balloon catheter with a drug coating. It is indicated for the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis.
SPNC: 24.86 (+0.17)
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Wed Aug 10, 3:27AM CDT
Spectranetics (NASDAQ:SPNC) was downgraded from Strong Buy to Buy at Needham today. The stock closed yesterday at $24.03 on volume of 445,000 shares, below average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)
Upgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Thu Aug 04, 3:16AM CDT
Spectranetics (NASDAQ:SPNC) was upgraded from Sell to Buy at UBS today. The stock closed yesterday at $23.67 on volume of 1.1 million shares, above average daily volume of 703,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 24.86 (+0.17)
Spectranetics Reports Second Quarter 2016 Revenue of $67.7 million
GlobeNewswire - Thu Jul 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended June 30, 2016. Highlights of the quarter, all compared with the three months ended June 30, 2015, include:
SPNC: 24.86 (+0.17)
Uptrend Call Working As Spectranetics Stock Rises 28.4% (SPNC)
Comtex SmarTrend(R) - Fri Jun 10, 1:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 28.41% as of today's recent price of $19.82.
SPNC: 24.86 (+0.17)
How are These Healthcare Stocks Faring? - Zimmer Biomet, Wright Medical, Spectranetics and Prestige Brands
PR Newswire - Fri Jun 03, 7:00AM CDT
In today's pre-market coverage, ActiveWallSt.com has these four Medical Appliances and Equipment stocks lined up for investors to review: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Wright Medical Group N.V. (NASDAQ: WMGI), The Spectranetics Corp. (NASDAQ: SPNC), and Prestige Brands Holdings Inc. (NYSE: PBH). Register now to access these stocks' trade alerts by clicking on the following link:
SPNC: 24.86 (+0.17), ZBH: 129.40 (+1.05), WMGI: 24.71 (+0.10), PBH: 47.99 (+0.29), WMGIZ: 1.35 (unch)
Shares of SPNC Up 26.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:55PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 26.27% as of today's recent price of $19.49.
SPNC: 24.86 (+0.17)
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
GlobeNewswire - Wed Jun 01, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)
SmarTrend Watching for Potential Pullback in Shares of Spectranetics After 5.77% Gain
Comtex SmarTrend(R) - Mon May 23, 4:32PM CDT
Spectranetics (NASDAQ:SPNC) traded in a range yesterday that spanned from a low of $16.56 to a high of $17.72. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $17.39 on volume of 534,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SPNC: 24.86 (+0.17)
Spectranetics to Present at the UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS Global Healthcare Conference on May 25, 2016, at the Grand Hyatt in New York City.
SPNC: 24.86 (+0.17)
Spectranetics reports 1Q loss
Automated Insights - Thu Apr 28, 6:28PM CDT
COLORADO SPRINGS, Colo. (AP) _ The Spectranetics Corp. (SPNC) on Thursday reported a loss of $17.3 million in its first quarter.
SPNC: 24.86 (+0.17)
Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
GlobeNewswire - Thu Apr 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. Highlights of the quarter, all compared with the three months ended March 31, 2015, include:
SPNC: 24.86 (+0.17)
12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
GlobeNewswire - Tue Apr 26, 5:30AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in London, England. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 24.86 (+0.17)
